the Dexcom G7 (more on this later). Having used a total of five different CGMs, I’ve noticed the key information that matters ...

Abbott and Dexcom have agreed to settle all of their remaining international legal disputes over patents related to their ...

is proud to announce that the Dexcom G7 Continuous Glucose Monitoring (CGM) System has now been added to the Alberta Drug Benefit List. In addition, the Alberta government has expanded the ...

The patent litigation relates to the companies’ continuous glucose monitor (CGM) technologies. Abbott and Dexcom are two ...

Over-the-counter continuous glucose monitors empower consumers with valuable health insights without the need for a doctor’s ...

Revenue for Q3 grew at just 2% y/y to $994.2 million, as headwinds mount even as the company is going through the launch of its G7 product. This is a big disappointment as DexCom has been a ...

We’re proud that people living in Canada can now access the latest AID offering with Dexcom G7, our smallest and most accurate CGM 2,” said André Côté, executive vice president and general ...

DexCom demonstrated strong product demand in third-quarter 2024, highlighted by record new patient starts in its core markets. The flagship G7 and DexCom ONE+ platforms continued to drive adoption ...

is proud to announce that the Dexcom G7 Continuous Glucose Monitoring (CGM) System has now been added to the Alberta Drug Benefit List. In addition, the Alberta government has expanded the ...

and now the first and only insulin pump in Canada that is integrated with both Dexcom G6 and Dexcom G7. “The commercial availability of this new offering is a testament to our decade-long partnership ...